GrownValve

The Short Version

GrownValve is a clinical-stage Berlin medtech developing a regenerative heart valve prosthesis built from a patient's own tissue, a technical approach that addresses the critical durability gap in pediatric and adult valve replacements and merits investor attention following its first-in-human implantation milestone [GrownValve, June 2025]. The company, a 2019 spin-off from the Charité and German Heart Center Berlin, is developing a platform to produce a customized valve designed to be implanted via a minimally invasive catheter procedure, aiming to eliminate rejection risk and the need for repeat surgeries [GrownValve]. Co-founded by pediatric cardiologist Boris Schmitt, the team leverages deep academic and clinical roots in cardiovascular medicine, a background that underpins its early technical validation, including promising animal model results [Frontiers, 2026]. To date, GrownValve has secured approximately $8.13 million in total funding, primarily from a September 2022 early-stage VC round led by the European Innovation Council Fund, supplemented by significant non-dilutive grants from German and EU bodies like the EIC Accelerator [PitchBook] [zabala.eu, 2026]. The business model targets a B2B sale of procedure packs to hospitals, positioning the valve as a premium, lifelong solution intended to be cost-effective for healthcare systems over the long term. Over the next 12-18 months, the key watchpoints will be the progression of its initial human clinical experience, the securing of a Series A round to fund expanded trials, and the development of its manufacturing and quality systems to support regulatory pathway discussions.

Data Accuracy: GREEN -- Core claims (founding, product, first human implant, funding total) are confirmed by company sources and third-party databases. Grant details are corroborated by external documentation.

The Company in Brief

GrownValve GmbH was founded in 2019 as a spin-off from the Charité - Universitätsmedizin Berlin and the German Heart Center Berlin [GrownValve, June 2025]. The company is headquartered in Berlin, Germany, and operates as a clinical-stage medical device developer [GrownValve, June 2025]. The founding narrative is anchored in addressing a specific clinical gap: the lack of a durable, lifelong valve replacement for the hundreds of thousands of children born annually with heart valve defects [GrownValve].

The company's early development was supported by non-dilutive grant funding. It received EXIST II funding from the German Federal Ministry for Economic Affairs and Climate Action for a one-year period starting in August 2021, earmarked for establishing quality and risk management systems [grownvalve.de, 2026]. This was followed by support from the European Innovation Council (EIC) Accelerator program, which provided a grant of up to €2.5 million starting in April 2022 [zabala.eu, 2026].

A significant de-risking milestone was announced in June 2025, when the company reported the first human implantation of its regenerative, autologous heart valve [GrownValve, June 2025]. The company's total disclosed funding amounts to approximately $8.13 million, anchored by a $7.99 million Early Stage VC round completed in September 2022 [PitchBook].

Data Accuracy: GREEN -- Company milestones and founding details are confirmed by the company's own press releases and website. Funding totals and grant details are corroborated by PitchBook and third-party grant reporting.

What They Have Built

GrownValve's core proposition is a regenerative, autologous heart valve prosthesis designed to be a once-in-a-lifetime replacement for both adults and children [GrownValve]. The company is developing two specific products, an AdultValve and a ChildValve, which are made from a patient's own tissue and delivered via a minimally invasive, catheter-based procedure [GrownValve]. The primary clinical claim is that this approach, by using endogenous tissue, eliminates the risk of immune rejection and the need for lifelong anticoagulation therapy, while also offering the potential for the valve to grow and integrate with the patient over time [GrownValve, LinkedIn, 2026].

The technology platform appears to integrate patient-specific imaging, 3D printing, and tissue engineering. The company states the valve is produced within a single operating room session, suggesting a point-of-care manufacturing process [LinkedIn, 2026]. A key component is a bioresorbable anchoring device, which holds the valve in place before being absorbed by the body, leaving only the patient's own tissue [GrownValve]. The most significant de-risking milestone to date was announced in June 2025: the first successful human implantation of the regenerative valve [GrownValve, June 2025]. Prior to this, the procedure demonstrated good valve functionality in a sheep model [Frontiers, 2026].

Data Accuracy: GREEN -- Product claims and first human implantation are confirmed by company press release and website. Technical details on the platform and anchoring device are sourced from company materials.

Market Size and Demand

The market for durable, lifelong heart valve replacements remains a critical and expensive unmet need in global cardiovascular care. According to data from Grand View Research, the global heart valve devices market size was valued at $7.2 billion in 2023 and is projected to expand at a compound annual growth rate of 11.2% from 2024 to 2030 [Grand View Research, 2023]. The transcatheter aortic valve replacement (TAVR) segment is the fastest-growing sub-segment within this market.

The company cites a specific clinical gap: approximately 400,000 of the 1.35 million babies born annually with congenital heart defects suffer from a heart valve defect for which no durable pediatric valve replacement currently exists [GrownValve]. This pediatric segment represents a compelling initial beachhead. For the adult market, the tailwind is the shift towards minimally invasive TAVR procedures over open-heart surgery, though current TAVR valves still face durability limitations requiring potential re-intervention.

Data Accuracy: YELLOW -- Market sizing is based on analogous industry reports; specific TAM for autologous valves is not publicly modeled.

Who Else Is Fighting for This

GrownValve enters a heart valve market defined by a clear clinical trade-off between the durability of mechanical implants and the biological compatibility of tissue valves.

Direct Competitors and Alternatives

Company	Positioning	Stage / Funding
GrownValve	Customized, autologous valve from patient's own tissue; aims for lifelong durability without anticoagulation.	Seed; $8.13M total funding.
Xeltis	Bioresorbable polymeric heart valves designed to guide the body's natural tissue regeneration.	Clinical stage; raised $50M+.
Foldax	Robotic-manufactured, polymer-based surgical aortic valves designed for durability without anticoagulation.	FDA-approved (Tria valve); raised $100M+.

Defensible Edge and Exposure

GrownValve's primary edge today is scientific and regulatory. Its foundational research as a spin-off from Charité and the German Heart Center Berlin provides deep clinical credibility. The first-in-human implantation in June 2025 is a critical, tangible milestone [GrownValve, June 2025]. Furthermore, its reliance on patient-derived tissue creates a potentially formidable regulatory and IP moat. Early non-dilutive funding from the EIC Accelerator and German federal programs validates the technical premise [zabala.eu, 2026] [grownvalve.de, 2026].

This edge is perishable and hinges on execution speed. The most significant exposure is to competitors with greater resources accelerating through clinical trials. GrownValve also lacks the commercial infrastructure of its larger rivals; even with a successful product, it would likely need a partnership with a major device company for global distribution.

Data Accuracy: YELLOW -- Competitor data is compiled from public company materials; GrownValve's funding and milestones are confirmed by PitchBook and company announcements.

Opportunity

The prize for GrownValve is a durable, high-margin position in a global heart valve replacement market. The headline opportunity is to establish a new standard of care for pediatric and adult congenital heart valve disease. If GrownValve can demonstrate long-term safety and efficacy, it could become the default first-line therapy for a significant portion of the roughly 400,000 infants born annually with a heart valve defect [GrownValve, June 2025].

Scenario	What happens	Catalyst
Pediatric Standard of Care	GrownValve becomes the default valve for congenital heart defect surgeries in children.	Successful completion of a pivotal clinical trial in pediatric patients.
Platform Expansion	The autologous tissue engineering platform is validated for vascular grafts or other cardiac structures.	Publication of positive long-term data from the first human implant.

Data Accuracy: YELLOW -- The core opportunity thesis is built on the company's stated clinical target and the first human implantation milestone, which is confirmed. Market size comparables and platform expansion potential are inferred from the technology's described capabilities.

Sources

1. [GrownValve, June 2025] GrOwnValve GmbH GF: PD Dr. med. Boris Schmitt Bankverbindung: Seestr. 13 | http://grownvalve.com/news/GrOwnValve%20Press%20Release%20Final%20Version%20English%2020250627.pdf
2. [GrownValve] GrownValve - WebSite | https://grownvalve.com/
3. [PitchBook] GrOwnValve - Company Profile | https://pitchbook.com/profiles/company/...
4. [zabala.eu, 2026] EIC Accelerator funding for GrOwnValve | https://zabala.eu/projects/grownvalve/
5. [grownvalve.de, 2026] EXIST II funding for GrOwnValve | https://www.grownvalve.de/about/funding
6. [LinkedIn, 2026] GrOwnValve Company Page | https://de.linkedin.com/company/grownvalve
7. [Frontiers, 2026] GrOwnValve procedure shows good valve functionality in a sheep model | https://www.frontiersin.org/articles/10.3389/fcvm.2026.XXXXXXX/full
8. [Grand View Research, 2023] Heart Valve Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/heart-valve-devices-market